VXRT - Vaxart's Vaccine Candidate Is a Pill Not a Shot. Does It Matter?
If you've ever ordered a piping hot pizza to your door, you already know that convenience is king. It's no secret that people are willing to pay for products that make their lives easier or less painful. But does that same principle hold up for products that consumers uniformly expect to be literally, physically painful, like getting vaccinated against the coronavirus?
Vaxart (NASDAQ: VXRT) is betting that, yes, people will prefer to avoid the pain of a jab if they have the option of taking its oral-pill vaccines. Its coronavirus candidate is shelf-stable, and intended for self-administration, making it significantly easier to distribute widely. However, that's assuming there will be a real market for vaccine tablets which will endure beyond the present phase of the pandemic, not to mention the assumption that tablets will be proven safe and effective in the clinical trials process. Now that there are a plethora of other coronavirus vaccines that are already approved for sale and actively gaining market share, can Vaxart still deliver for its investors?
Image source: Getty Images
For further details see:
Vaxart's Vaccine Candidate Is a Pill, Not a Shot. Does It Matter?